SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Pulmonology Consultation — John Locke

PatientJohn Locke
Date of birth1966-09-08
IdentifiersMRN HR-EN001-SYN; SSN (made up) 000-01-8305
Document date2026-03-26
AuthorAmbrose Nwankwo-Fairfax, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

A 59-year-old never-smoker with a cough since his late thirties and wheeze and breathlessness, worse every winter, in city air, and by open coal and wood fires at home. Please confirm the diagnosis (asthma, COPD from non-tobacco exposures, or both), advise on CT, and recommend treatment and pulmonary rehabilitation. [S]

Urgency: Routine, within two to three weeks; he is not in distress and has a reliever. [S]

Questions for the consultant:

History of Present Illness

Mr. Locke is seen at the request of Dr. Hartwell-Osei. He has had a cough since his late thirties, with wheeze and breathlessness that have grown over the years; symptoms are worst in winter, in cold air, in the city, and by smoky fires, and ease in summer and in the country. He has never smoked or vaped and has had no occupational dust or fume exposure. He lived about 30 years in a large city near main roads and for the past year has lodged in a country house with open coal and wood fires, which have been out of use for two weeks. He has had no hemoptysis, fevers, night sweats, weight loss, nasal symptoms, reflux, or breathlessness lying flat. He has never had an oral corticosteroid course or an emergency visit for breathing. On albuterol as needed he uses one or two doses a day. His father and brother died of consumption. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

8 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometryTwo puffs every 4 hours as neededRespiratory tract route2026-03-12 to 2026-03-26completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayTwo inhalations twice daily plus one as needed; no more than 12 a dayRespiratory tract route2026-03-26activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluationresolvedconfirmed R05.3S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit.
Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at homeactiveconfirmed Z77.110S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted.
Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPDactiveconfirmed J45.40S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R).

Physical Exam

Vital signs recorded on 2026-03-26; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralThin, comfortable at rest, speaking in full sentences
RespiratoryProlonged expiration with scattered expiratory wheeze; no crackles; no clubbing; oxygen saturation 95 percent
CardiovascularRegular rhythm; jugular venous pressure not raised; no edema
Ears, nose, and throatNasal mucosa normal; no polyps

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-26FEV1 --pre bronchodilation2.11LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
2026-03-26Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation3.71LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
2026-03-26FEV1/FVC0.57{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cmLowS
2026-03-26FEV1 measured/predicted62%GLI Global race-neutral equations for a man of 59, 178 cmLowS
2026-03-26FEV1 --post bronchodilation2.49LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
2026-03-26Forced vital capacity [Volume] Respiratory system --post bronchodilation4.02LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
2026-03-26FEV1/FVC --post bronchodilation0.62{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitationLowS
2026-03-26Diffusion capacity.carbon monoxide26.4mL/min/mm[Hg]Lower limit of normal, GLI 2017 race-neutral equations; predicted 26.9NormalS
2026-03-26Fractional concentration of exhaled nitric oxide41[ppb]In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS)HighS
2026-03-26Six minute walk test430mPredicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 mLowS
2026-03-26Total score [ACT]13{score}S

Assessment

Data reviewed: Spirometry this morning (GLI Global race-neutral equations): FEV1 2.11 L (62 percent predicted) and FVC 3.71 L before bronchodilator, FEV1/FVC 0.57; 15 minutes after albuterol 400 mcg, FEV1 2.49 L (+380 mL, 11 percent of predicted) and FVC 4.02 L, FEV1/FVC 0.62 (lower limit of normal 0.67); DLCO 26.4 mL/min/mmHg (predicted 26.9); FeNO 41 ppb; six-minute walk 430 m with lowest saturation 94 percent. CT of the chest today without contrast, with expiratory images: diffuse bronchial wall thickening and mosaic attenuation with air trapping; no emphysema, bronchiectasis, nodules, or interstitial disease. From the first visit: eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, alpha-1 antitrypsin 131 mg/dL, NT-proBNP 58 pg/mL, interferon-gamma release assay negative (0.02 IU/mL), and a chest X-ray with mild hyperinflation only. Asthma Control Test 13 today. [S]

Plan of Treatment